A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Wells Fargo raised the firm’s price target on Bristol Myers (BMY) to $62 from $60 and keeps an Equal Weight rating on the shares. While ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

CNBC's Jim Cramer breaks down why he's keeping an eye on shares of Bristol Myers. Irv Gotti, Music Executive Behind Ja Rule ...

Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.